Business Wire

Global Immunization Possible by 2022 With Fair Vaccine Distribution, Says WHO COVID-19 Special Envoy

Share

The World Government Summit Dialogues saw world leaders outline solutions to humanity’s most urgent challenges during the virtual event on 9-10 March.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210311005126/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The World Government Summit Dialogues saw world leaders outline solutions to humanity’s most urgent challenges (Photo: AETOSWire)

Dr. David Nabarro, Special Envoy on COVID-19 to the World Health Organization (WHO), claimed the unfair weighting of vaccine access in favour of rich countries will delay the global recovery from the healthcare and economic crises, potentially beyond 2022.

“While the COVAX effort is commendable, if a few countries take the majority of the supplies and leave minimal cash and vaccine supplies behind for the rest, this is not ethical,” Dr. Nabarro said.

The current “free-for-all” approach to vaccine supplies with “a small number of nations trying to outbid one another”, doesn’t work. But “fair access to vaccine for everybody, the objective for immunization, at least by 2022, is a reasonable prospect,” he said.

Earlier, Dr. Tedros Ghebreyesus, Director-General, WHO, said: “Vaccine nationalism will only prolong the pandemic, and the human and economic suffering that goes with it. Health must be seen not as a cost to be contained but as an investment in productive and resilient populations, and a key to sustainable development.”

Later, the Right Honourable Lord Martin Rees, President, the Royal Society, said reasons to study and explore other planets must be carefully considered. He claimed: “The idea of Elon Musk to have a million people settle on Mars is a dangerous delusion. Living on Mars is no better than living on the South Pole or the tip of Mount Everest.

“The only reason for humans to go to space would be for adventure. To live on Mars is not going to be easy. Mars has a hostile environment.”

His thoughts were backed-up by the eminent astrophysicist, Dr. Neil deGrasse Tyson, who said: “To ship a billion people to another planet to help them survive a catastrophe on earth seems unrealistic.”

The World Government Summit Dialogues convened leaders from around the world virtually to predict the trends that will shape the future, post-pandemic society. For more details about the event, visit: https://www.worldgovernmentsummit.org/

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

APCO Worldwide
Mahmoud Kandil, +971551266801
mkandil@apcoworldwide.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 04:41:00 EET | Press release

Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm

Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 03:15:00 EET | Press release

Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E

IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 23:10:00 EET | Press release

IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerstone of IonQ’s global strategy,” said Niccolo de Masi, Chairman and CEO of IonQ. “QuantumBasel continues to be a critical innovation node for our company as

Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 22:50:00 EET | Press release

Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which translate into thinner, more discreet and comfortable products. Its high compression capability enables s

SES Acknowledges Moody’s Rating Action and Reiterates Deleveraging Commitments17.12.2025 22:36:00 EET | Press release

SES S.A. (“SES” or the “Company”), a leading space solutions company, acknowledges the credit rating action announced by Moody’s Investor Service today, which follows the release of SES’ Q3 2025 results and Intelsat integration update. SES management reiterates that the Company continues to execute on its strategy with a clear plan to strengthen its key credit metrics over time. Consistent with this plan, it remains management’s intention to de-lever and return to credit metrics that are commensurate with investment grade, with a policy objective of reducing adjusted net leverage1 to at least 3.0x or below. Today’s rating action does not change the Company’s ability to operate its business, serve customers, or execute its strategic plan. SES maintains a balanced weighted average debt maturity profile of approximately five years, and the rating action from Moody’s is not expected to have a material impact on the interest payable under the Company’s existing debt facilities. SES also ben

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye